Profile data is unavailable for this security.
About the company
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme. It partners with Alnylam Pharmaceuticals.
- Revenue in EUR (TTM)37.65bn
- Net income in EUR11.22bn
- LocationSanofi SA54 rue la BoetiePARIS 75008FranceFRA
- Phone+33 153774000
- Fax+33 153774463
Mergers & acquisitions
|Acquired company||Deal status||Date||Date /|
|SAN:PAR since |
|Kymab Ltd||Announced||11 Jan 2021||11 Jan 2021Announced||4.09%||1.45bn|
|Kiadis Pharma NV||Announced||02 Nov 2020||02 Nov 2020Announced||6.00%||254.17m|
|Principia Biopharma Inc||Deal completed||17 Aug 2020||17 Aug 2020Deal completed||-4.04%||3.67bn|